ASCO Plenary Sessions

Impact, legacy, future

Andrae Vandross, Vinay Prasad, Sham Mailankody

Research output: Contribution to journalArticle

Abstract

The ASCO annual meeting draws a large crowd of physicians, cancer researchers, policy makers, and industry representatives. The crown jewel of the annual events is the Plenary session where impactful, influential and visible abstracts are selected for the largest audience. Plenary topics are frequently paired with concurrent New England Journal or Lancet publications. Here, we review 9 years of ASCO plenary sessions. Several themes emerge. First, many of the topics selected have indeed been practice changing, such as the use of ALK inhibitors for ALK rearranged NSCLC, or checkpoint inhibitors in metastatic melanoma. Second, although some plenary topics seemed destined to change practice, they ultimately falter, such as the use of Cetuximab in NSCLC, vaccine therapy for follicular lymphoma, and even Bevacizumab in metastatic renal cell cancer. Who could have forseen bevacizumab displaced by several VEGF TKIs? Third, negative trials are rare among Plenary sessions, but when they are presented they are immensely important. Examples include a seminal study using CA-125 levels to guide treatment of relapsed ovarian cancer, the use of lapatinib combined with traztuzumab in the adjuvant treatment of HER2 + disease, and studies showing no survival benefit to upfront bevacizumab in glioblastoma multiforme. Fourth, we note a large industry presence among Plenary sessions, as the Industry in part sponsored 62% of Plenary abstracts. Ultimately a review of 9 years of ASCO plenary reveals the plenary for what it is: a conservative selection of abstracts that, at the time, are thought to change the face of oncology. Time, however, is the true arbiter, and some succeed in this quest, while others falter. ASCO plenary sessions reveal the influence, legacy and future of cancer care.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalSeminars in Oncology
Volume43
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Industry
Active Immunotherapy
New England
Follicular Lymphoma
Glioblastoma
Administrative Personnel
Crowns
Renal Cell Carcinoma
Ovarian Neoplasms
Vascular Endothelial Growth Factor A
Publications
Melanoma
Neoplasms
Research Personnel
Physicians
Therapeutics
Bevacizumab
lapatinib
Cetuximab

Keywords

  • ASCO
  • Breaking abstract
  • Influence
  • Medical conferences
  • Plenary Sessions

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

ASCO Plenary Sessions : Impact, legacy, future. / Vandross, Andrae; Prasad, Vinay; Mailankody, Sham.

In: Seminars in Oncology, Vol. 43, No. 3, 01.06.2016, p. 321-326.

Research output: Contribution to journalArticle

Vandross, Andrae ; Prasad, Vinay ; Mailankody, Sham. / ASCO Plenary Sessions : Impact, legacy, future. In: Seminars in Oncology. 2016 ; Vol. 43, No. 3. pp. 321-326.
@article{819663d63bd34a8abcd76b2c36a68fdf,
title = "ASCO Plenary Sessions: Impact, legacy, future",
abstract = "The ASCO annual meeting draws a large crowd of physicians, cancer researchers, policy makers, and industry representatives. The crown jewel of the annual events is the Plenary session where impactful, influential and visible abstracts are selected for the largest audience. Plenary topics are frequently paired with concurrent New England Journal or Lancet publications. Here, we review 9 years of ASCO plenary sessions. Several themes emerge. First, many of the topics selected have indeed been practice changing, such as the use of ALK inhibitors for ALK rearranged NSCLC, or checkpoint inhibitors in metastatic melanoma. Second, although some plenary topics seemed destined to change practice, they ultimately falter, such as the use of Cetuximab in NSCLC, vaccine therapy for follicular lymphoma, and even Bevacizumab in metastatic renal cell cancer. Who could have forseen bevacizumab displaced by several VEGF TKIs? Third, negative trials are rare among Plenary sessions, but when they are presented they are immensely important. Examples include a seminal study using CA-125 levels to guide treatment of relapsed ovarian cancer, the use of lapatinib combined with traztuzumab in the adjuvant treatment of HER2 + disease, and studies showing no survival benefit to upfront bevacizumab in glioblastoma multiforme. Fourth, we note a large industry presence among Plenary sessions, as the Industry in part sponsored 62{\%} of Plenary abstracts. Ultimately a review of 9 years of ASCO plenary reveals the plenary for what it is: a conservative selection of abstracts that, at the time, are thought to change the face of oncology. Time, however, is the true arbiter, and some succeed in this quest, while others falter. ASCO plenary sessions reveal the influence, legacy and future of cancer care.",
keywords = "ASCO, Breaking abstract, Influence, Medical conferences, Plenary Sessions",
author = "Andrae Vandross and Vinay Prasad and Sham Mailankody",
year = "2016",
month = "6",
day = "1",
doi = "10.1053/j.seminoncol.2016.03.001",
language = "English (US)",
volume = "43",
pages = "321--326",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - ASCO Plenary Sessions

T2 - Impact, legacy, future

AU - Vandross, Andrae

AU - Prasad, Vinay

AU - Mailankody, Sham

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The ASCO annual meeting draws a large crowd of physicians, cancer researchers, policy makers, and industry representatives. The crown jewel of the annual events is the Plenary session where impactful, influential and visible abstracts are selected for the largest audience. Plenary topics are frequently paired with concurrent New England Journal or Lancet publications. Here, we review 9 years of ASCO plenary sessions. Several themes emerge. First, many of the topics selected have indeed been practice changing, such as the use of ALK inhibitors for ALK rearranged NSCLC, or checkpoint inhibitors in metastatic melanoma. Second, although some plenary topics seemed destined to change practice, they ultimately falter, such as the use of Cetuximab in NSCLC, vaccine therapy for follicular lymphoma, and even Bevacizumab in metastatic renal cell cancer. Who could have forseen bevacizumab displaced by several VEGF TKIs? Third, negative trials are rare among Plenary sessions, but when they are presented they are immensely important. Examples include a seminal study using CA-125 levels to guide treatment of relapsed ovarian cancer, the use of lapatinib combined with traztuzumab in the adjuvant treatment of HER2 + disease, and studies showing no survival benefit to upfront bevacizumab in glioblastoma multiforme. Fourth, we note a large industry presence among Plenary sessions, as the Industry in part sponsored 62% of Plenary abstracts. Ultimately a review of 9 years of ASCO plenary reveals the plenary for what it is: a conservative selection of abstracts that, at the time, are thought to change the face of oncology. Time, however, is the true arbiter, and some succeed in this quest, while others falter. ASCO plenary sessions reveal the influence, legacy and future of cancer care.

AB - The ASCO annual meeting draws a large crowd of physicians, cancer researchers, policy makers, and industry representatives. The crown jewel of the annual events is the Plenary session where impactful, influential and visible abstracts are selected for the largest audience. Plenary topics are frequently paired with concurrent New England Journal or Lancet publications. Here, we review 9 years of ASCO plenary sessions. Several themes emerge. First, many of the topics selected have indeed been practice changing, such as the use of ALK inhibitors for ALK rearranged NSCLC, or checkpoint inhibitors in metastatic melanoma. Second, although some plenary topics seemed destined to change practice, they ultimately falter, such as the use of Cetuximab in NSCLC, vaccine therapy for follicular lymphoma, and even Bevacizumab in metastatic renal cell cancer. Who could have forseen bevacizumab displaced by several VEGF TKIs? Third, negative trials are rare among Plenary sessions, but when they are presented they are immensely important. Examples include a seminal study using CA-125 levels to guide treatment of relapsed ovarian cancer, the use of lapatinib combined with traztuzumab in the adjuvant treatment of HER2 + disease, and studies showing no survival benefit to upfront bevacizumab in glioblastoma multiforme. Fourth, we note a large industry presence among Plenary sessions, as the Industry in part sponsored 62% of Plenary abstracts. Ultimately a review of 9 years of ASCO plenary reveals the plenary for what it is: a conservative selection of abstracts that, at the time, are thought to change the face of oncology. Time, however, is the true arbiter, and some succeed in this quest, while others falter. ASCO plenary sessions reveal the influence, legacy and future of cancer care.

KW - ASCO

KW - Breaking abstract

KW - Influence

KW - Medical conferences

KW - Plenary Sessions

UR - http://www.scopus.com/inward/record.url?scp=84967157552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967157552&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2016.03.001

DO - 10.1053/j.seminoncol.2016.03.001

M3 - Article

VL - 43

SP - 321

EP - 326

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3

ER -